The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

45 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Evaluation of bisbenzamidines as inhibitors for matriptase-2.EBI
University Of Bonn
Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.EBI
Bristol-Myers Squibb Research & Development
Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.EBI
Southern Research
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.EBI
Bristol-Myers Squibb
Active site-directed plasmin inhibitors: Extension on the P2 residue.EBI
Kobe Gakuin University
Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI
Bristol-Myers Squibb
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.EBI
Aurigene Discovery Technologies
Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.EBI
Heidelberg University
Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.EBI
Queensland University Of Technology
Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.EBI
Southeast University
Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate.EBI
Tokyo University Of Pharmacy And Life Sciences
Pyridine and pyridinone-based factor XIa inhibitors.EBI
Bristol-Myers Squibb
Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.EBI
TBA
Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.EBI
Bristol-Myers Squibb
Discovery of a Cyclic Boronic Acidß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.EBI
Rempex Pharmaceuticals
Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.EBI
Bristol-Myers Squibb R & D
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI
Bristol-Myers Squibb
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.EBI
Bristol-Myers Squibb
Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.EBI
Astellas Pharma
Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.EBI
Astellas Pharma
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.EBI
Bristol-Myers Squibb
Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.EBI
Chinese Academy Of Sciences
Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.EBI
Central Pharmaceutical Research Institute
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.EBI
Lg Life Sciences
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.EBI
Dupont Pharmaceuticals
Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.EBI
Universit£
Tetrahydro-isoquinoline-based factor Xa inhibitors.EBI
Boehringer Mannheim
Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds.EBI
Corvas International
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.EBI
Peking University
Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.EBI
Merck Research Laboratories
Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.EBI
Merck
P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.EBI
Eli Lilly
Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.EBI
Merck
Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.EBI
Merck Research Laboratories
Structure-based design of novel potent nonpeptide thrombin inhibitors.EBI
Boehringer Ingelheim Pharma
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.EBI
Axys Pharmaceuticals
Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.EBI
Axys Pharmaceuticals
Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.EBI
Dupont Pharmaceuticals
The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase.EBI
Roche Discover Welwyn
Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.EBI
Dupont Pharmaceuticals
In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors.EBI
3-Dimensional Pharmaceuticals
Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.EBI
Biotech Research Institute
1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.EBI
Northwestern University Medical School
Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.EBI
Collegeville